RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Genomic Vision Stock

Genomic Vision P/S 2024

Genomic Vision P/S

6.22

Ticker

GV.PA

ISIN

FR0011799907

WKN

A110TM

As of Aug 1, 2024, Genomic Vision's P/S ratio stood at 6.22, a -79.16% change from the 29.84 P/S ratio recorded in the previous year.

The Genomic Vision P/S history

Genomic Vision Aktienanalyse

What does Genomic Vision do?

Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Genomic Vision's P/S Ratio

Genomic Vision's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Genomic Vision's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Genomic Vision's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Genomic Vision’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Genomic Vision stock

What is the price-to-earnings ratio of Genomic Vision?

The price-earnings ratio of Genomic Vision is currently 6.22.

How has the price-earnings ratio of Genomic Vision changed compared to last year?

The price-to-earnings ratio of Genomic Vision has increased by -79.16% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Genomic Vision high compared to other companies?

Yes, the price-to-earnings ratio of Genomic Vision is high compared to other companies.

How does an increase in the price-earnings ratio of Genomic Vision affect the company?

An increase in the price-earnings ratio of Genomic Vision would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Genomic Vision affect the company?

A decrease in the price-earnings ratio of Genomic Vision would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Genomic Vision?

Some factors that influence the price-earnings ratio of Genomic Vision are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Genomic Vision pay?

Over the past 12 months, Genomic Vision paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genomic Vision is expected to pay a dividend of 0 EUR.

What is the dividend yield of Genomic Vision?

The current dividend yield of Genomic Vision is .

When does Genomic Vision pay dividends?

Genomic Vision pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genomic Vision?

Genomic Vision paid dividends every year for the past 0 years.

What is the dividend of Genomic Vision?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genomic Vision located?

Genomic Vision is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genomic Vision kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genomic Vision from 8/1/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Genomic Vision pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Genomic Vision in the year 2023?

In the year 2023, Genomic Vision distributed 0 EUR as dividends.

In which currency does Genomic Vision pay out the dividend?

The dividends of Genomic Vision are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Genomic Vision

Our stock analysis for Genomic Vision Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genomic Vision Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.